Pathologist-level classification of histopathological melanoma images with deep neural networks. (2019) Hekler A, Utikal JS, Enk AH, Klode J, Schadendorf D, Jansen P, Franklin C, et al. Journal article Superior skin cancer classification by the combination of human and artificial intelligence. (2019) Hekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, et al. Journal article Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. (2019) Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, et al. Journal article A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. (2019) Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, et al. Journal article Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data (vol 119, pg 30, 2019) (2019) Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, et al. Journal article, Erratum Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’ [Eur J Cancer, 119 (September 2019) Pages 30–34](S0959804919304095)(10.1016/j.ejca.2019.07.009) (2019) Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, et al. Journal article, Erratum Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab (2019) Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, et al. Journal article Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors (2019) Moreira A, Loquai C, Pfoefer C, Kaehler KC, Knauss S, Heppt MV, Gutzmer R, et al. Journal article Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 (2018) Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, et al. Journal article